key: cord-0937047-mu9fj199 authors: Meyer, Keith C.; Avery, Robin K. title: Optimizing virus protection in lung transplant recipients: Don’t drop the ball date: 2021-05-01 journal: Am J Transplant DOI: 10.1111/ajt.16609 sha: 395b5266be897c81df43df3589663dcd1b8d107f doc_id: 937047 cord_uid: mu9fj199 The SARS-CoV-2 pandemic has brought the threat of viral infections to the fore. Even seemingly healthy, young individuals can die if they contract the virus, and immunocompromised individuals may be at greater risk of a fatal outcome should they become infected. But many other viruses pose potential threats to the well-being of solid organ transplant recipients. Chief among viral threats to lung transplant recipients are cytomegalovirus and community-acquired respiratory viruses. Fortunately, we have developed strategies to prevent or blunt the impact of CMV on lung transplant recipients, but a high degree of vigilance must be maintained to screen and prevent the passage of transmissible viruses from donor to recipient. The SARS-CoV-2 pandemic has brought the threat of viral infections to the fore. Even seemingly healthy, young individuals can die if they contract the virus, 1 and immunocompromised individuals may be at greater risk of a fatal outcome should they become infected. 2 But many other viruses pose potential threats to the well-being of solid organ transplant recipients. Chief among viral threats to lung transplant recipients are cytomegalovirus and community-acquired respiratory viruses. Fortunately, we have developed strategies to prevent or blunt the impact of cytomegalovirus on lung transplant recipients, 3 but a high degree of vigilance must be maintained to screen and prevent the passage of transmissible viruses from donor to recipient. 4 Since the advent of highly effective vaccines against common childhood illnesses (Table 1) , measles, mumps, German measles, and chicken pox outbreaks and epidemics have almost completely disappeared from the United States and most other developed countries. Nonetheless, even fully vaccinated individuals could still contract and develop infections from these viruses, but the herd immunity attained by universal childhood vaccination programs makes it very unlikely that a significant outbreak or epidemic can arise. However, increasing hostile attitudes in a substantial segment of the population toward childhood vaccination and the unfounded notion that childhood vaccines are linked to autism 5 may abrogate the protection that herd immunity provides and lead to outbreaks or even epidemics that can threaten the well-being of immunocompromised transplant recipients, even if they have received vaccinations prior to transplantation. If vaccines are available to protect patients who must receive intense posttransplant immunosuppression, but using live attenuated virus vaccines, such as measles, mumps, rubella (MMR) and Varicella, in immunosuppressed transplant recipients is considered to be contraindicated-it seems logical that it is important to screen solid organ transplant candidates for evidence of protective, virus-specific immune responses. Then, if needed, these vaccines can be given to candidates prior to transplantation. However, emerging data in pediatric solid organ recipients suggest that live virus vaccinations may be given safely to carefully selected, clinically stable patients following transplantation. 6 Hostetler et al 7 Year licensed in United States. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review COVID-19 in immunocompromised hosts: what we know so far Infection prophylaxis and management of viral infection Infectious disease transmission in solid organ transplantation: donor evaluation, recipient risk, and outcomes of transmission Vaccination as a cause of autism-myths and controversies Live vaccines after pediatric solid organ transplant: Proceedings of a consensus meeting Immunity to varicella, measles, and mumps in patients evaluated for lung transplantation Waning antibody levels and avidity: implications for MMR vaccine-induced protection Seroprevalence to measles virus after vaccination or natural infection in an adult population Immunity to vaccine-preventable viral infections in australians being evaluated for liver transplantation Analysis of measlesmumps-rubella (MMR) titers of recovered COVID-19 patients